| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Cd69 |
| Uniprot No | Q07108 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 62-199aa |
| 氨基酸序列 | SVGQYNCPGQYTFSMPSDSHVSSCSEDWVGYQRKCYFISTVKRSWTSAQNACSEHGATLAVIDSEKDMNFLKRYAGREEHWVGLKKEPGHPWKWSNGKEFNNWFNVTGSDKCVFLKNTEVSSMECEKNLYWICNKPYK |
| 预测分子量 | 18.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD69重组蛋白的3篇示例参考文献(注：以下为假设性示例，实际文献请通过学术数据库查询)：
---
1. **文献名称**: *"Expression and functional analysis of recombinant CD69 in T lymphocyte activation"*
**作者**: García-Monzón et al.
**摘要**: 研究通过大肠杆菌系统表达重组CD69蛋白，证实其与细胞表面配体(如Galectin-1)结合，抑制T细胞受体(TCR)信号通路，调节早期免疫活化反应。
---
2. **文献名称**: *"CD69 recombinant protein binds to oxidized LDL and modulates macrophage inflammation"*
**作者**: Kimura T, et al.
**摘要**: 利用哺乳动物细胞表达体系制备功能性CD69重组蛋白，发现其通过识别氧化低密度脂蛋白(oxLDL)调控巨噬细胞炎症因子分泌，提示CD69在动脉粥样硬化中的潜在作用。
---
3. **文献名称**: *"Crystal structure of the CD69 ectodomain reveals a conserved C-type lectin-like fold"*
**作者**: Sánchez-Madrid F, et al.
**摘要**: 解析CD69胞外段重组蛋白的晶体结构，揭示其C型凝集素样结构域的关键结合位点，为设计靶向CD69的免疫调节药物提供结构基础。
---
如需具体文献，建议在PubMed或Web of Science中搜索关键词 **"CD69 recombinant protein"** 或 **"CD69 protein function"**，筛选近五年高被引研究。
CD69. also known as CLEC2C, is a type II transmembrane glycoprotein belonging to the C-type lectin receptor family. It was first identified as an early activation marker on immune cells, including T cells, B cells, natural killer (NK) cells, and macrophages. Structurally, CD69 consists of a short cytoplasmic tail, a transmembrane domain, and an extracellular C-type lectin-like domain. Its expression is rapidly induced upon cellular activation through antigen recognition, cytokine signaling, or stress stimuli, making it a critical player in both innate and adaptive immune responses.
Functionally, CD69 regulates immune cell activation, proliferation, and migration. It modulates signaling pathways such as NF-κB and MAPK, influencing cytokine production and cell survival. CD69 also interacts with ligands like sphingosine-1-phosphate (S1P) receptor 1. controlling lymphocyte egress from lymphoid organs. Emerging studies highlight its role in immune tolerance, autoimmunity, and inflammatory diseases, with altered CD69 expression linked to conditions like rheumatoid arthritis, multiple sclerosis, and cancer.
Recombinant CD69 protein is produced using expression systems (e.g., mammalian or insect cells) to mimic native protein structure and function. It serves as a vital tool for studying CD69-ligand interactions, signaling mechanisms, and therapeutic targeting. Researchers employ it in assays (ELISA, flow cytometry), antibody development, and drug screening. Its therapeutic potential includes blocking CD69-mediated pathways in autoimmune disorders or enhancing anti-tumor immunity. As a biomarker, recombinant CD69 aids in monitoring immune activation states in clinical samples. Ongoing research continues to unravel its multifaceted roles in immune regulation and disease pathogenesis.
×
